NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Comparative Real World Effectiveness of SQ Sublingual Immunotherapy (SLIT)-Tablets vs. Controls in Allergic Rhinitis and Asthma

NCT05476484

CompletedN/A

Sponsor: ALK-Abelló A/S

Conditions: Allergic Rhinitis, Asthma, Allergy

Interventions: SQ SLIT-tablet

Countries: Denmark

To assess the impact of SQ SLIT-tablets (SQ Grass SLIT-tablet and SQ HDM SLIT-tablet) in Danish and Swedish allergic rhinitis (AR) patients, with or without asthma, between 2007-2020.

Eligibility overview

Sex: ALL

Age: 5 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

AR-patients identified by having at least two dispensations of prescribed AR medications for two consecutive years and/or ICD10-codes of AR in specialty care

For the SQ SLIT-tablet cohort:

\- at least 2 dispensations within 365 days of SQ SLIT-tablets (ATC: V01AA02 and V01AA03)

For the control cohort:

\- unexposed subjects will be identified from the study population of AR-patients that may be eligible to receive SQ SLIT-tablets, but have not dispensed a prescription of SQ SLIT-tablets during the index year of the case or prior to that year

Exclusion Criteria:

\- Any allergy immunotherapy treatment prior to the index event

Locations (1)

Hørsholm, Copenhagen, Denmark